Interestingly, the addition of anti-PD-1 antibody with monoclonal anti-rat neu antibodies 7.16.4 and 7.6.5 and class II HER2-DC1 vaccine not only significantly delayed the tumor growth but also enhanced and quadrupled the survival rate from control mice (Figures 9B,C). This evidence concerns the gene ERBB2 and neoplasm.